Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: David Winkler who wrote (601)	5/4/1998 10:46:00 PM
From: Tech Master	Read Replies (1) \| Respond to of 2135

David: A post from the TCLN thread: Talk : Biotechnology : Techniclone (TCLN) \| Previous \| ------ \| Respond \| To: Terry D. (1597 ) From: Davis Marshall Monday, May 4 1998 8:36PM ET Reply # of 1599 You know, Terry, I've followed ENMD a long time. It's local and they are very vocal. No one I've heard of has ever duplicated Dr. Folkman's work. These are nude mice which are highly vascularized, they are actually designed to work best with the two proteins. I think one is human and the other is animal. It's hard enough to get one drug approved, let alone two new ones in combo.- To their credit Dr. Folkman said today that he only knows it shows efficacy in mice and Dr. Holaday said it would be at least five years until market approval. I've seen worse (the stock was brought public by D.H.Blair, a broker/dealer owned by Morty Davis - currently enjoying 13 inditements for stock stuff). Techniclone's antiangiogenesis patents cover the killing of tumors, everyone else only shrinks tumors, they still exist but depend on an apple a day to stay shrunk. If ENMD is treating tumors by killing vasculature, thus killing the tumor, then Entremed is infringing on Techniclone patents. As would be anyone else. Think about it. I wish ENMD great success. Techniclone is ahead of Entremed and every other company which is trying to kill tumors. Not only do they have the jump on them but it appears they will be part of them, through patents. We threaders know something about aa but the general public doesn't, witness the ENMD runup today. This is one playing field on which it will be very difficult to ignore TCLN. I wonder how the company will present their argument?